News - Asia-Pacific, Otsuka


Current filters:


Popular Filters

Otsuka’s Samsca, first ADPKD therapy, approved in Japan


Japanese drugmaker Otsuka Pharmaceutical says it has become the first company in the world to obtain…

Asia-PacificJapanNephrology and HepatologyOtsukaPharmaceuticalRegulationSamsca

Japanese approval for Forxiga and Lonsurf


Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story


A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided…

Asia-PacificAstex PharmaceuticalsBiotechnologyFinancialInterviewsMergers & AcquisitionsOtsukaUKUSA

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU


Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Otsuka's Samsca gains additional indication in Japan


Japanese drugmaker Otsuka (TYO: 4768) says that its vasopressin V2 receptor antagonist Samsca (tolvaptan)…

Asia-PacificNephrology and HepatologyOtsukaPharmaceuticalRegulationSamscatolvaptan

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European


Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Taiho Pharma files for approval of cancer drug TAS-102 in Japan


Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka (TYO: 4768) says that it submitted an…

Asia-PacificOncologyOtsukaPharmaceuticalRegulationTaiho PharmaceuticalTAS-102

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Claris Lifesciences dips on sale of infusions business


Indian drugmaker Claris Lifesciences (CLAI: BO) has dipped 4% to 264 rupees, declining over 6% from day's…

Asia-PacificClaris LifesciencesMergers & AcquisitionsMitsui & CoOtsukaPharmaceutical

Otsuka files Abilify, first antipsychotic for major depressive disorder in Japan


Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) has filed an additional indication for Abilify (aripiprazole)…


Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin


Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko


Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Additional indication for Otsuka’s Abilify in Japan


Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) said last week that it has received new regulatory…


Otsuka Pharma and UCB re-focus collaboration


Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…


Back to top